Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3CNS 3Sarcoma 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 21Meningioma 6Gastro-enteropancreatic neuroendocrine tumor 6Pheochromocytoma 3Paraganglioma 3Prostatic Neoplasms 2Neuroblastoma 2Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Merkel Cell 2Adenoma, Islet Cell 2Somatostatin Receptor-positive Neuroendocrine Tumor 1Sarcoma, Synovial 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Extensive Stage Small Cell Lung Cancer 1Esthesioneuroblastoma, Olfactory 1Disease Progression 1Digestive System Neuroendocrine Tumor G1 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1

Interventions

Specimen Handling 4lutetium Lu 177 dotatate 3gallium Ga 68 dotatate 3Magnetic Resonance Spectroscopy 3olaparib 2cabozantinib 2belzutifan 2Temozolomide 2Nivolumab 2Fluorodeoxyglucose F18 2Biopsy 26-fluorodopamine 23-Iodobenzylguanidine 2tipifarnib 1talazoparib 1spartalizumab 1pembrolizumab 1pegfilgrastim 1lanreotide 1guadecitabine 1fluorodopa F 18 1fludarabine phosphate 1copper dotatate CU-64 1atezolizumab 1Stem Cell Transplantation 1Phenoxybenzamine 1Lutetium-177 1Lutetium 1Ipilimumab 1Interleukin-13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pheochromocytoma × lutetium Lu 177 dotatate × 1 year × Clear all
NCT06607692 2026-06-04

LUPARPED

Fundación de investigación HM

Phase 1/2 Recruiting
25 enrolled
CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡